These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 18279450)
1. Establishing the role of cytokine therapy in advanced renal cell carcinoma. Gore ME; De Mulder P BJU Int; 2008 May; 101(9):1063-70. PubMed ID: 18279450 [TBL] [Abstract][Full Text] [Related]
2. [Cytokine therapy for metastatic renal cell carcinoma]. Eto M; Naito S Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for renal cell cancer in the era of targeted therapy. Coppin C Expert Rev Anticancer Ther; 2008 Jun; 8(6):907-19. PubMed ID: 18533800 [TBL] [Abstract][Full Text] [Related]
7. [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy]. Kobori G; Maegawa M; Ushida H; Maekawa S; Inoue K; Kaneko Y; Ohmori K; Nishimura K Hinyokika Kiyo; 2002 Jul; 48(7):455-7. PubMed ID: 12229188 [TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic renal cell carcinoma. Reeves DJ; Liu CY Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348 [TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Samlowski WE; Majer M; Boucher KM; Shrieve AF; Dechet C; Jensen RL; Shrieve DC Cancer; 2008 Nov; 113(9):2539-48. PubMed ID: 18780316 [TBL] [Abstract][Full Text] [Related]
10. Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer. Logan TF; Bensadoun ES Thorax; 2005 Jul; 60(7):610-1. PubMed ID: 15994271 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
12. Renal cell carcinoma and interferon at the millennium. Pastore RD; Pfeffer LM; Nanus DM Cancer Invest; 2001; 19(3):281-91. PubMed ID: 11338886 [No Abstract] [Full Text] [Related]
13. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034 [TBL] [Abstract][Full Text] [Related]
14. Current treatment of renal cell carcinoma. De Mulder PH; van Herpen CM; Mulders PA Ann Oncol; 2004; 15 Suppl 4():iv319-28. PubMed ID: 15477330 [No Abstract] [Full Text] [Related]
15. [Successful preoperative interferon-alpha therapy of advanced renal cell carcinoma with tumor thrombus extending into the inferior vena cava: a case report]. Kato T; Madono K; Saito J; Kakuta Y; Tanigawa G; Yazawa K; Hosomi M; Ito K Hinyokika Kiyo; 2008 Feb; 54(2):119-22. PubMed ID: 18323170 [TBL] [Abstract][Full Text] [Related]
16. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile. Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C Oncology; 2009; 76(1):69-76. PubMed ID: 19047813 [TBL] [Abstract][Full Text] [Related]
17. GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts. Vassilakos A; Lee Y; Viau S; Feng N; Jin H; Chai V; Wang M; Avolio T; Wright J; Young A Int J Oncol; 2009 Jan; 34(1):33-42. PubMed ID: 19082475 [TBL] [Abstract][Full Text] [Related]
18. [A case of interferon-alpha-resistant renal cell carcinoma responding to interleukin-2 therapy]. Kobori G; Yamada H; Higashi Y Hinyokika Kiyo; 2008 Oct; 54(10):657-9. PubMed ID: 19048930 [TBL] [Abstract][Full Text] [Related]
19. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome. Westermann J; Hecker AC; Flörcken A; Dörken B; Pezzutto A J Immunother; 2009; 32(6):667-75. PubMed ID: 19483643 [TBL] [Abstract][Full Text] [Related]